Younossi Z, Anstee QM, Marietti M et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol 2018;15:11–20.

PubMed  Google Scholar 

Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023;77:1335–1347.

PubMed  Google Scholar 

Younossi ZM, Golabi P, de Avila L et al. The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis. J Hepatol 2019;71:793–801.

PubMed  Google Scholar 

Rinella ME, Lazarus JV, Ratziu V et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol 2023;79:1542–1556.

CAS  PubMed  Google Scholar 

Montano-Loza AJ, Meza-Junco J, Prado CMM et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol 2012;10:166–731.

PubMed  Google Scholar 

Ooi PH, Hager A, Mazurak VC et al. Sarcopenia in chronic liver disease: impact on outcomes. Liver Transpl 2019;25:1422–1438.

PubMed  Google Scholar 

Henin G, Loumaye A, Leclercq IA, Lanthier N. Myosteatosis: diagnosis, pathophysiology and consequences in metabolic dysfunction-associated steatotic liver disease. JHEP Rep 2024;6:100963.

PubMed  Google Scholar 

Kalyani RR, Corriere M, Ferrucci L. Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases. Lancet Diabetes Endocrinol 2014;2:819–829.

PubMed  PubMed Central  Google Scholar 

Cleasby ME, Jamieson PM, Atherton PJ. Insulin resistance and sarcopenia: mechanistic links between common co-morbidities. J Endocrinol 2016;229:R67–R81.

CAS  PubMed  Google Scholar 

Prado CM, Batsis JA, Donini LM, Gonzalez MC, Siervo M. Sarcopenic obesity in older adults: a clinical overview. Nat Rev Endocrinol 2024;20:261–277.

PubMed  Google Scholar 

Liu C, Wong PY, Chung YL et al. Deciphering the “obesity paradox” in the elderly: a systematic review and meta-analysis of sarcopenic obesity. Obes Rev. 2023. https://doi.org/10.1111/obr.13534.

Article  PubMed  Google Scholar 

Ueng KC, Chiang CE, Chao TH et al. 2023 guidelines of the Taiwan society of cardiology on the diagnosis and management of chronic coronary syndrome. Acta Cardiol Sin 2023;39:4–96.

PubMed  PubMed Central  Google Scholar 

Chien KL, Hsu HC, Su TC et al. Constructing a point-based prediction model for the risk of coronary artery disease in a Chinese community: a report from a cohort study in Taiwan. Int J Cardiol 2012;157:263–268.

PubMed  Google Scholar 

Cunningham JJ. A reanalysis of the factors influencing basal metabolic rate in normal adults. Am J Clin Nutr 1980;33:2372–2374.

CAS  PubMed  Google Scholar 

Donini Lorenzo M, Busetto L, Bischoff Stephan C et al. Definition and diagnostic criteria for sarcopenic obesity: ESPEN and EASO consensus statement. Obes Facts 2022;15:321–335.

CAS  PubMed  PubMed Central  Google Scholar 

Janssen I, Heymsfield SB, Ross R. Low relative skeletal muscle mass (sarcopenia) in older persons is associated with functional impairment and physical disability. J Am Geriatr Soc 2002;50:889–896.

PubMed  Google Scholar 

Hwang Y-C, Cho I-J, Jeong I-K, Ahn KJ, Chung HY. Differential association between sarcopenia and metabolic phenotype in Korean young and older adults with and without obesity. Obesity 2017;25:244–251.

CAS  PubMed  Google Scholar 

Chang CJ, Wu CH, Chang CS et al. Low body mass index but high percent body fat in Taiwanese subjects: implications of obesity cutoffs. Int J Obes Relat Metab Disord 2003;27:253–259.

PubMed  Google Scholar 

LeBoff MS, Greenspan SL, Insogna KL et al. The clinician’s guide to prevention and treatment of osteoporosis. Osteoporos Int 2022;33:2049–2102.

CAS  PubMed  PubMed Central  Google Scholar 

Kleiner DE, Brunt EM, Van Natta M et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313–1321.

PubMed  Google Scholar 

Grundy SM, Stone NJ, Bailey AL et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2019;139:e1082–e1143.

PubMed  Google Scholar 

Goff DC Jr, Lloyd-Jones DM, Bennett G et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014;129:S49–S73.

PubMed  Google Scholar 

Han E, Chun HS, Lee Y-H et al. MAFLD might be better in identifying subjects with sarcopenia or cardiovascular risk than NAFLD: a nationwide study. J Gastroenterol Hepatol 2023;38:1598–1609.

CAS  PubMed  Google Scholar 

Koo BK, Kim D, Joo SK et al. Sarcopenia is an independent risk factor for non-alcoholic steatohepatitis and significant fibrosis. J Hepatol 2017;66:123–131.

PubMed  Google Scholar 

Gan D, Wang L, Jia M et al. Low muscle mass and low muscle strength associate with nonalcoholic fatty liver disease. Clin Nutr 2020;39:1124–1130.

PubMed  Google Scholar 

Lee YH, Kim SU, Song K et al. Sarcopenia is associated with significant liver fibrosis independently of obesity and insulin resistance in nonalcoholic fatty liver disease: nationwide surveys (KNHANES 2008–2011). Hepatology 2016;63:776–786.

CAS  PubMed  Google Scholar 

Harring M, Golabi P, Paik JM et al. Sarcopenia among patients with nonalcoholic fatty liver disease (NAFLD) is associated with advanced fibrosis. Clin Gastroenterol Hepatol 2023;21:2876-2888.e5.

CAS  PubMed  Google Scholar 

Wong VW, Vergniol J, Wong GL et al. Diagnosis of fibrosis and cirrhosis using liver stiffness measurement in nonalcoholic fatty liver disease. Hepatology 2010;51:454–462.

CAS  PubMed  Google Scholar 

Petta S, Di Marco V, Cammà C, Butera G, Cabibi D, Craxì A. Reliability of liver stiffness measurement in non-alcoholic fatty liver disease: the effects of body mass index. Aliment Pharmacol Ther 2011;33:1350–1360.

CAS  PubMed  Google Scholar 

Wong VW-S, Irles M, Wong GL-H et al. Unified interpretation of liver stiffness measurement by M and XL probes in non-alcoholic fatty liver disease. Gut 2019;68:2057–2064.

CAS  PubMed  Google Scholar 

Dasarathy S, Merli M. Sarcopenia from mechanism to diagnosis and treatment in liver disease. J Hepatol 2016;65:1232–1244.

PubMed  PubMed Central  Google Scholar 

Al Saedi A, Debruin DA, Hayes A, Hamrick M. Lipid metabolism in sarcopenia. Bone 2022;164:116539.

CAS  PubMed  Google Scholar 

García PS, Cabbabe A, Kambadur R, Nicholas G, Csete M. Brief-reports: elevated myostatin levels in patients with liver disease: a potential contributor to skeletal muscle wasting. Anesth Analg 2010;111:707–709.

PubMed  Google Scholar 

Qiu J, Thapaliya S, Runkana A et al. Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB-mediated mechanism. Proc Natl Acad Sci USA 2013;110:18162–18167.

CAS  PubMed  PubMed Central  Google Scholar 

Hong HC, Hwang SY, Choi HY et al. Relationship between sarcopenia and nonalcoholic fatty liver disease: the Korean Sarcopenic Obesity Study. Hepatology 2014;59:1772–1778.

CAS  PubMed  Google Scholar 

Barzilay JI, Cotsonis GA, Walston J et al. Insulin resistance is associated with decreased quadriceps muscle strength in nondiabetic adults aged ≥70 years. Diabetes Care 2009;32:736–738.

CAS  PubMed  PubMed Central  Google Scholar 

Kim TN, Park MS, Yang SJ et al. Prevalence and determinant factors of sarcopenia in patients with type 2 diabetes. Diabetes Care 2010;33:1497–1499.

PubMed  PubMed Central  Google Scholar 

Song R, Li Z, Zhang Y, Tan J, Chen Z. Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults. Liver Int 2024;44:1051–1060.

CAS  PubMed  Google Scholar 

Henson JB, Simon TG, Kaplan A, Osganian S, Masia R, Corey KE. Advanced fibrosis is associated with incident cardiovascular disease in patients with non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2020;51:728–736.

CAS  PubMed  PubMed Central  Google Scholar 

Lee H, Lee Y-H, Kim SU, Kim HC. Metabolic dysfunction-associated fatty liver disease and incident cardiovascular disease risk: a nationwide cohort study. Clin Gastroenterol Hepatol 2021;19:2138-2147.e10.